Pterostilbene,
does it really help with Antioxidant effects and healthspan extension?
research showsIn a manufacturer-run trial of 60 adults receiving Silbinol, a Pterocarpus marsupium extract containing 90% pterostilbene, at 200 mg/day for eight weeks, GSH, SOD, and lipid-peroxidation measures did not differ between groups. A separate 80-person RCT found that pterostilbene alone increased LDL by 17.1 mg/dL (p=0.001). The direct human antioxidant trial was null, resulting in D with 30 points; the LDL signal is handled separately as a safety caution.
ads claimMarketing links a resveratrol analog, SIRT1 and Nrf2 pathways, and higher bioavailability to antioxidant and longevity effects. Human data concern short-term safety, blood pressure, lipids, and antioxidant-enzyme surrogates, not aging-related clinical outcomes.
Useful facts when choosing a product
- Human trials used 100-250 mg/day.
- Silbinol in the 60-person manufacturer trial was a Pterocarpus marsupium extract containing 90% pterostilbene.
- Pterostilbene alone increased LDL by 17.1 mg/dL in the 80-person trial (p=0.001).
- No trial directly assessed human healthspan, mortality, or lifespan.
What the research actually shows
The Riche 2014 trial assigned 80 adults with dyslipidemia to four groups for six to eight weeks and found a 17.1 mg/dL LDL increase with pterostilbene alone (p=0.001). The Majeed 2023 trial gave Silbinol 200 mg/day for eight weeks to 60 healthy adults; Silbinol is a Pterocarpus marsupium extract containing 90% pterostilbene, not pure pterostilbene. GSH, SOD, and lipid-peroxidation measures showed no between-group benefit, and neither trial assessed healthspan or survival.
Why this is classified as D (30)
The direct human antioxidant trial found null between-group results for GSH, SOD, and lipid peroxidation, supporting D with 30 points. Healthspan extension remains ungraded, and the LDL increase is recorded as a safety caution.
Counterpoint. A blood-pressure reduction was observed in the short-term high-dose group, but it is a different endpoint from the antioxidant and healthspan claim judged here.
Rejudgment record. Reassessment (cross-check reflected) — A 60-person direct antioxidant trial found null between-group results for GSH, SOD, and lipid peroxidation; human healthspan evidence is absent, and the LDL increase is separated as safety
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Antioxidant effects (surrogate markers) | D | Direct human trial was null |
| Healthspan extension | ? | No efficacy literature assessed human healthspan, mortality, or lifespan |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Riche DM et al. 2014 | Randomized double-blind placebo-controlled metabolic trial | 80 | Study product support from a pterostilbene supplier | Blood pressure, lipids, and weight | Lower blood pressure in the high-dose group and a 17.1 mg/dL LDL increase with monotherapy were observed together. | Supportive |
| Majeed M et al. 2023 | Randomized double-blind placebo-controlled safety and biomarker trial | 60 | Sami-Sabinsa manufacturer study | Safety and serum antioxidant profile | Silbinol, a Pterocarpus marsupium extract containing 90% pterostilbene, showed no between-group difference in GSH, SOD, or lipid peroxidation. | Key |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Pterostilbene x Antioxidant effects and healthspan extension — Evidence Grade D·30. 2 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/antioxidant-aging/pterostilbene-antioxidant-longevity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.